SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum... Show more
The 10-day moving average for SABS crossed bullishly above the 50-day moving average on October 13, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SABS just turned positive on November 12, 2025. Looking at past instances where SABS's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
SABS moved above its 50-day moving average on October 17, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SABS advanced for three days, in of 190 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 100 cases where SABS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SABS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SABS broke above its upper Bollinger Band on November 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SABS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.937) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (322.723).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SABS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Industry Biotechnology
A.I.dvisor indicates that over the last year, SABS has been loosely correlated with LPTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then LPTX could also see price increases.
| Ticker / NAME | Correlation To SABS | 1D Price Change % | ||
|---|---|---|---|---|
| SABS | 100% | +4.28% | ||
| LPTX - SABS | 46% Loosely correlated | +368.57% | ||
| MGX - SABS | 37% Loosely correlated | -15.45% | ||
| TECX - SABS | 30% Poorly correlated | -0.63% | ||
| INKT - SABS | 28% Poorly correlated | +0.15% | ||
| GRI - SABS | 28% Poorly correlated | +1.08% | ||
More | ||||